KalVista price target raised to $29 from $28 at Citizens

Citizens raised the firm’s price target on KalVista (KALV) to $29 from $28 and keeps an Outperform rating on the shares. Ekterly posted a strong Q4 launch with $35M in revenue, well above expectations, driven by robust start forms and refills, though some holiday-related seasonality was evident, the analyst tells investors in a research note. While early performance implies an annualized run-rate above 2026 consensus, confirmation of sustained demand will hinge on a rebound in start forms in 1Q26, with refills expected to remain the primary revenue driver, the firm says.